Anzeige
Meldung des Tages: Öl bricht über $108 und Wedgemount dreht die Produktion genau jetzt wieder an.

Galmed Pharmaceuticals News

Aktie
WKN:  A1XFUX ISIN:  IL0011313900 US-Symbol:  GLMD Branche:  Biotechnologie Land:  Israel
0,5722 $
+0,0059 $
+1,04%
0,48738 € 30.04.26
Depot/Watchlist
Marktkapitalisierung *
4,03 Mio. €
Streubesitz
98,04%
KGV
-0,71
Index-Zuordnung
-

Galmed Pharmaceuticals News

14.04.26 - PR Newswire
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers PR Newswire
09.04.26 - PR Newswire
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol PR Newswire
31.03.26 - PR Newswire
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 PR Newswire
30.01.26 - PR Newswire
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire
08.12.25 - PR Newswire
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Galmed Announces Acceptance of a Late-​Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR Newswire
04.12.25 - PR Newswire
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH PR Newswire
01.12.25 - PR Newswire
Galmed Issues CEO Letter to Shareholders
Galmed Issues CEO Letter to Shareholders PR Newswire
26.11.25 - PR Newswire
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
18.11.25 - PR Newswire
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire
17.11.25 - PR Newswire
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo ...
28.08.25 - PR Newswire
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
25.08.25 - PR Newswire
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value PR Newswire
27.05.25 - PR Newswire
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-​Billion-Dollar Expansion Potential Beyond NASH PR Newswire
22.05.25 - PR Newswire
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire
13.05.25 - PR Newswire
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
Galmed Reports Significant Anti-​Fibrotic Effects of Aramchol in PSC Models PR Newswire
06.05.25 - PR Newswire
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »